Eligibility for intravenous thrombolysis in suspected acute myocardial infarction.
暂无分享,去创建一个
[1] R. Peto,et al. Wider inclusion criteria needed for thrombolytic therapy. , 1989, Annals of internal medicine.
[2] J. Herlitz,et al. Delay time in suspected acute myocardial infarction and the importance of its modification , 1989, Clinical cardiology.
[3] L. Ekström,et al. Effect of a media campaign on delay times and ambulance use in suspected acute myocardial infarction. , 1989, The American journal of cardiology.
[4] L. Goldman,et al. Candidates for thrombolysis among emergency room patients with acute chest pain. Potential true- and false-positive rates. , 1989, Annals of internal medicine.
[5] F. Van de Werf,et al. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.
[6] A. M. Skene,et al. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.
[7] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[8] M. O'Rourke,et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. , 1988, Circulation.
[9] M. Cerqueira,et al. Ventricular function and infarct size: the Western Washington Intravenous Streptokinase in Myocardial Infarction Trial. , 1988, Journal of the American College of Cardiology.
[10] F. Sheehan,et al. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial. , 1988, Circulation.
[11] National Heart Foundation Of Australia Coronary Thrombolysi Group. CORONARY THROMBOLYSIS AND MYOCARDIAL SALVAGE BY TISSUE PLASMINOGEN ACTIVATOR GIVEN UP TO 4 HOURS AFTER ONSET OF MYOCARDIAL INFARCTION , 1988, The Lancet.
[12] H. White,et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. , 1987, The New England journal of medicine.
[13] J. Herlitz,et al. Five-year mortality rate in relation to enzyme-estimated infarct size in acute myocardial infarction. , 1987, American heart journal.
[14] R. Balcon,et al. What proportion of patients with myocardial infarction are suitable for thrombolysis? , 1987, British heart journal.
[15] W. Littler,et al. ELIGIBILITY FOR THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION , 1987, The Lancet.
[16] P. Shah,et al. Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. , 1987, The American journal of cardiology.
[17] P. Serruys,et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. , 1986, Journal of the American College of Cardiology.
[18] A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. , 1986, The New England journal of medicine.
[19] Use of the initial electrocardiogram to predict in-hospital complications of acute myocardial infarction. , 1986, The New England journal of medicine.
[20] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[21] M S Golden,et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.
[22] B. Sobel,et al. Estimation of Infarct Size in Man and its Relation to Prognosis , 1972, Circulation.